HC Wainwright set a $11.00 target price on Evofem Biosciences (NASDAQ:EVFM) in a research note released on Monday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on the stock. Cantor Fitzgerald reaffirmed an overweight rating on shares of Evofem Biosciences in a research report on Friday, November 23rd. Oppenheimer set a $9.00 target price on shares of Evofem Biosciences and gave the company a buy rating in a research report on Friday, November 16th. Finally, ValuEngine raised shares of Evofem Biosciences from a hold rating to a buy rating in a research report on Thursday, November 1st. Six research analysts have rated the stock with a buy rating, The company has an average rating of Buy and an average price target of $10.40.

Shares of EVFM stock opened at $3.85 on Monday. Evofem Biosciences has a twelve month low of $1.79 and a twelve month high of $12.90.

Evofem Biosciences (NASDAQ:EVFM) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.34). As a group, sell-side analysts expect that Evofem Biosciences will post -5.77 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new position in Evofem Biosciences in the third quarter valued at about $879,000. Heartland Advisors Inc. acquired a new position in Evofem Biosciences in the third quarter valued at about $1,319,000. Millennium Management LLC lifted its position in Evofem Biosciences by 6,497.4% in the second quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock valued at $1,989,000 after buying an additional 722,643 shares during the last quarter. Finally, Woodford Investment Management Ltd lifted its position in Evofem Biosciences by 28.5% in the second quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock valued at $25,998,000 after buying an additional 2,127,659 shares during the last quarter. 77.81% of the stock is currently owned by institutional investors.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.

See Also: Institutional Investors

Analyst Recommendations for Evofem Biosciences (NASDAQ:EVFM)

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.